Skip to Content

Join the 'Emtricitabine / tenofovir Alafenamide' group to help and get support from people like you.

Emtricitabine / tenofovir Alafenamide News

FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection

Posted 8 Feb 2018 by

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer ...

Fighting HIV on Multiple Fronts Might Lead to Vaccine

Posted 20 Sep 2017 by

WEDNESDAY, Sept. 20, 2017 – A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies. Two separate research groups completely protected their own sets of lab monkeys from HIV infection using this combination vaccination strategy, albeit in two very different ways. One group inoculated their monkeys with a "cocktail" of ...

Could a Monetary Perk Help Keep HIV Patients on Their Meds?

Posted 22 Jun 2017 by

WEDNESDAY, June 21, 2017 – There are mixed results from a new study on the use of monetary rewards to help boost the odds that HIV-infected patients will enter care, and take their meds as directed. The study, conducted at HIV clinics in New York City and Washington, D.C., found that financial incentives such as gift cards could improve the likelihood that HIV patients would take antiretroviral ...

Americans With HIV Staying on Lifesaving Meds Longer

Posted 31 May 2017 by

WEDNESDAY, May 31, 2017 – More Americans with HIV are sticking with medications that turn a fatal disease into a manageable condition, a new study shows. "This represents a lot of people who are not dying and not infecting others," said study corresponding author Ira Wilson, chair of Brown University's Health Services Policy and Practice Department, in Providence, R.I. "These differences ...

Doctors Seeing More HIV Patients With Multidrug Resistance

Posted 1 Dec 2016 by

THURSDAY, Dec. 1, 2016 – A significant number of people with HIV have strains of the AIDS-causing virus that are resistant to both older and newer drugs, researchers report. The researchers looked at 712 HIV patients worldwide whose infection was not controlled by antiretroviral drugs. They found that 16 percent of patients whose infection was resistant to modern drugs had HIV mutations linked ...

FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy

Posted 5 Apr 2016 by

FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in ...

Ask a Question

Further Information

Related Condition Support Groups

HIV Infection

Related Drug Support Groups


Emtricitabine / tenofovir Alafenamide Patient Information at